Anti-EBV Latent Membrane Protein 1 [CS 1-4]

Tool Details

*FOR RESEARCH USE ONLY

• Name: Anti-EBV Latent Membrane Protein 1 [CS 1-4]
• Clone: CS 1-4
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Molecular weight: 57-66 kDa
• Reactivity: Virus
• Host: Mouse
• Application: IHC ; IHC ; IF ; IP ; WB
• Description: Anti-EBV (CS1) is a latent membrane protein 1 antibody, which detects a specific epitope upon LMP fusion protein in B-cell transformations, following EBV infection.
• Immunogen: P03230
• Immunogen uniprot id: P03230
• Isotype: IgG1 kappa
• Myeloma used: P3X63Ag8.653
• Recommended controls: EBV transformed lymphoblastoid cell lines

Target Details

• Target: Epstein-Barr Virus, Latent Membrane Protein 1 (EBV-LMP1)
• Molecular weight: 57-66 kDa
• Tissue cell line specificity: EBV transformed lymphoblastoid cell lines
• Target background: A combination of four pooled antibodies which collectively detect the latent membrane protein (LMP) of EBV, an important effector protein in B-cell transformation under EBV infection, across 20 geographically distinct EBV isolates. EBV is a human herpesvirus that establishes a life-long persistence in the host. The virus infects the vast majority of the world's adult population and is well known for its association with a broad spectrum of benign and malignant diseases. These include infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma, and is causally associated with lymphoid and epithelial malignancies, including post-transplant lymphoproliferative disorders, Hodgkin's disease, anaplastic nasopharyngeal carcinoma and gastric carcinomas. Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a transforming protein that affects multiple cell signalling pathways and contributes to EBV-associated oncogenesis. LMP1 can be expressed in some states of EBV latency, and significant induction of full-length LMP1 is also observed frequently during virus reactivation into the lytic cycle. LMP1 is critical for EBV-infected cell activation, adhesion and survival, and is usually expressed in the malignant cells. These antibodies were created to examine various aspects of LMP expression in B-cell lines transformed in vitro, detecting LMPs from 20 geographically varied EBV isolates.

Applications

• Application: IHC ; IHC ; IF ; IP ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
• Shipping conditions: Shipping at 4° C

Related Tools

• Related tools: Anti-EBV Latent Membrane Protein 1 [LMPO24]

References

• Ye et al. 2020. J Cancer. 11(5):1257-1269. PMID: 31956372.
• Shi et al. 2019. Theranostics. 9(9):2424-2438. PMID: 31131045.
• Wang et al. 2017. Virol Sin. 32(5):423-430. PMID: 29116594.
• Martin et al. 2016. J Virol. 90(19):8520-30. PMID: 27440880.
• Castrale et al. 2011. J Transplant. 2011:865957. PMID: 21559262.
• Flanagan et al. 2003. J Gen Virol. 84(Pt 7):1871-9. PMID: 12810882.
• Localization of the Epstein-Barr virus protein LMP 1 to exosomes.
• Nakatsuka et al. 2002. J Clin Oncol. 20(20):4255-60. PMID: 12377970.
• Pyothorax-associated lymphoma: a review of 106 cases.
• Xu et al. 2002. J Virol. 76(8):4080-6. PMID: 11907247.
• Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.
• Ascani et al. 1997. Ann Oncol. 8(11):1133-8. PMID: 9426333.
• Pyothorax-associated lymphoma: description of the first two cases detected in Italy.
• Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.
• Rowe et al. 1991. J Exp Med. 173(1):147-58. PMID: 1845872.
• Rowe et al. 1987. J Gen Virol. 68 ( Pt 6):1575-86. PMID: 2438376.
• Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.